Data / Drug companies / Waylis Therapeutics LLC
Waylis Therapeutics LLC: 26 products in the FDA NDC directory, labeler code 80725
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Waylis Therapeutics LLC (labeler code 80725) lists 26 products in the FDA National Drug Code Directory, covering 12 finished drugs by generic name. By type: 26 prescription drugs. Its main marketing category is new drug applications (NDA). The newest product started marketing on September 11, 2025.
The request: Watch Waylis Therapeutics LLC (FDA labeler code 80725): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 80725
- Products in commercial distribution
- 26
- Packages
- 27
- Finished drugs by generic name
- 12
- Prescription products
- 26
- Over the counter products
- 0
- Controlled substance products
- Schedule IV 6
- Flagged as original packager
- 23 of 23 products that carry the flag
- Started marketing in the last 12 months
- 0
- Earliest marketing start
- April 8, 2021
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| New drug applications (NDA) | 23 | 88.5% |
| Generic drugs (ANDA) | 3 | 11.5% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 26 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Carvedilol phosphate | 4 | 10 |
| Hydroxyurea | 4 | 14 |
| Carvedilol | 4 | 35 |
| Eszopiclone | 3 | 29 |
| Diazepam | 3 | 51 |
| Flutamide | 2 | 1 |
| Busulfan | 1 | 8 |
| Thioguanine | 1 | 1 |
| Paromomycin sulfate | 1 | 1 |
| Dutasteride and tamsulosin hydrochloride | 1 | 4 |
| Rabeprazole sodium | 1 | 20 |
| Chlorambucil | 1 | 1 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Capsule | 8 | 30.8% |
| Tablet, film coated | 6 | 23.1% |
| Capsule, extended release | 4 | 15.4% |
| Tablet | 4 | 15.4% |
| Tablet, coated | 3 | 11.5% |
| Tablet, delayed release | 1 | 3.8% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Droxia | 80725-840 | Capsule | New drug applications (NDA) | September 11, 2025 |
| Droxia | 80725-830 | Capsule | New drug applications (NDA) | September 11, 2025 |
| Droxia | 80725-820 | Capsule | New drug applications (NDA) | September 11, 2025 |
| Hydrea | 80725-810 | Capsule | New drug applications (NDA) | September 11, 2025 |
| Jalyn | 80725-809 | Capsule | New drug applications (NDA) | March 1, 2024 |
| Lunesta | 80725-012 | Tablet, coated | New drug applications (NDA) | August 15, 2023 |
| Lunesta | 80725-011 | Tablet, coated | New drug applications (NDA) | August 15, 2023 |
| Lunesta | 80725-010 | Tablet, coated | New drug applications (NDA) | August 15, 2023 |
| Tabloid | 80725-630 | Tablet | New drug applications (NDA) | May 15, 2023 |
| Myleran | 80725-620 | Tablet, film coated | New drug applications (NDA) | May 15, 2023 |
| Leukeran | 80725-610 | Tablet, film coated | New drug applications (NDA) | May 15, 2023 |
| Coreg | 80725-142 | Tablet, film coated | New drug applications (NDA) | March 15, 2023 |
| Coreg | 80725-141 | Tablet, film coated | New drug applications (NDA) | March 15, 2023 |
| Coreg | 80725-140 | Tablet, film coated | New drug applications (NDA) | March 15, 2023 |
| Coreg | 80725-139 | Tablet, film coated | New drug applications (NDA) | March 15, 2023 |
| Coreg CR | 80725-388 | Capsule, extended release | New drug applications (NDA) | November 7, 2022 |
| Coreg CR | 80725-387 | Capsule, extended release | New drug applications (NDA) | November 7, 2022 |
| Coreg CR | 80725-385 | Capsule, extended release | New drug applications (NDA) | November 7, 2022 |
| Coreg CR | 80725-383 | Capsule, extended release | New drug applications (NDA) | November 7, 2022 |
| Aciphex | 80725-243 | Tablet, delayed release | New drug applications (NDA) | May 15, 2022 |
| Valium | 80725-006 | Tablet | New drug applications (NDA) | April 4, 2022 |
| Valium | 80725-005 | Tablet | New drug applications (NDA) | April 4, 2022 |
| Valium | 80725-004 | Tablet | New drug applications (NDA) | April 4, 2022 |
| Eulexin | 80725-600 | Capsule | Generic drugs (ANDA) | November 12, 2021 |
| Eulexin | 80725-143 | Capsule | Generic drugs (ANDA) | November 12, 2021 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.